Last reviewed · How we verify
Pembrolizumab plus chemotherapy — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Pembrolizumab plus chemotherapy (Pembrolizumab plus chemotherapy) — Samsung Medical Center.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Pembrolizumab plus chemotherapy TARGET | Pembrolizumab plus chemotherapy | Samsung Medical Center | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Pembrolizumab plus chemotherapy CI watch — RSS
- Pembrolizumab plus chemotherapy CI watch — Atom
- Pembrolizumab plus chemotherapy CI watch — JSON
- Pembrolizumab plus chemotherapy alone — RSS
Cite this brief
Drug Landscape (2026). Pembrolizumab plus chemotherapy — Competitive Intelligence Brief. https://druglandscape.com/ci/pembrolizumab-plus-chemotherapy. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab